The Six Keys for Effective Deviation Investigators

In the pharmaceutical and biotechnology industry, the key to sustainable quality is good product, process, and method development, combined with well-trained and educated personnel using well-defined systems to provide consistent results. However, as with all systems, there are occasional faults that occur. In our industry, we define these faults as “deviations.” 

Deviation investigations are fundamental tools for properly identifying the root cause of these faults and creating a plan for corrective and preventive actions to bring the system back to sustainable control. But in many companies, the number of deviations is excessive and the time to complete the investigations exceeds reasonable standards. What, then, are the keys to ensure that the people assigned to investigate these deviations can do their jobs effectively, find the root cause, and propose the changes that will eliminate these faults and ensure they do not recur? 

1. Analytical Mindset 

The first key to being an effective investigator is the ability and desire to solve puzzles. Every deviation is like a mystery, with many factors which may be the root cause. Some of these factors, though, might be false leads which, if not properly evaluated, could result in an incorrect conclusion and a repeat of the deviation. Evaluating the capability and interest of an individual to engage in this type of exercise is the responsibility of management. Often companies make the mistake of thinking that anyone can learn the skill and perform effectively. There certainly are skills to be learned, but without this inherent interest and capability, the individual will never achieve a satisfactory level of performance.  

2. Process Understanding 

It is surprising how many companies assign personnel to investigate deviations who have minimal or no technical expertise in the process or product issue being evaluated. Companies would never assign someone to operate a complex process without training the individual and evaluating their competence. But often trying to unravel a root cause for a complex process is left to individuals who have never had anything but a limited overview or familiarity with the area under investigation. Taking the time to educate the investigator in the nuances of the process, product, or method will pay dividends in the speed and effectiveness of the deviation investigation. 

3. Technical Writing Skill 

While technical writing skill is often quoted as an important skill for deviation investigators, this is really a misnomer. The true skill required is not writing a complex technical document, but the ability to distill what is often a complex and multifaceted issue down into a clear and concise story. A critical component of every investigation is the summary report that will serve to allow company personnel and external regulators to understand the problem, the solution, and how to effectively and permanently correct the deviation. In today’s world of texts, emails, and cell phones, the ability to write clearly and concisely is a skill not necessarily well-developed in people joining our industry. But this is a skill that can be learned and should be a critical part of the training and education of personnel assigned to be investigators. 

 4. Knowledge of Problem Solving/Risk Evaluation Tools 

There are many paths and tools available to get to the root cause of a deviation and evaluate its risk to the product or process. Pareto Charts, Fishbone Diagrams, the 5 Whys, Failure Mode and Effects Analysis (FMEA), and Risk Matrices, among many others, are all tools that can be used depending on the nature of the investigation. The selection of the wrong tool or the ineffective use of the correct one may result in a failure to find the true root cause and result in repeated instances of the same deviation. Training and education on how to choose and use the right tool must be an integral part of training for each investigator.  

5. Time 

Regardless of skill level, if an investigator is not given sufficient time to conduct their analysis, evaluate the risks, and draft their report, the quality and effectiveness of the investigation will be compromised. With some experience, well-trained investigators can estimate the time required to conduct and complete an investigation. When staffing for and assigning investigations, management must understand that ineffective investigations resulting in repeat deviations are far more costly than having sufficient resources available to conduct proper and thorough investigations that result in timely corrective and preventive actions.  It is management’s responsibility to listen to their investigators’ estimates regarding the time required and the resources needed to do a proper evaluation.  

6. Management Support for Objective Analysis 

As with solving any mystery, an investigator must start their assessment without preconceived opinions or pressures. In our industry, where we are dealing with supply and cost pressures, it is a constant concern that investigators feel the weight of their efforts impacting the disposition of product. This pressure may wrongly influence investigators to construct an outcome that does not negatively impact product decisions. It is management’s responsibility to provide the leadership and organizational structure that separates the investigator from this influence. How this can be achieved is unique for every organization but, in many cases, companies can have investigators as part of an independent group, similar to internal auditors, and leave the final decisions regarding product impact as a separate activity conducted by the quality group utilizing the investigators’ findings. 

Conclusion 

The ability of investigators to conduct effective, objective assessments of deviations is a critical element of every company’s ability to sustainably produce safe and effective high-quality products. Selecting and training investigators who have the skills and environment to conduct well-structured and thorough analyses is the most cost-effective approach to dealing with deviations encountered during product development and manufacture. 

____________________________________________________________________________

QxP Vice President Mike Levitt started his more than 30-year career in pharma leadership as Director of Production Operations at Eli Lilly and Company back in 1989. 

Check out Mike’s other recent blogs: “Is it Time to Outsource Internal Auditing?” and “Pharmaceutical Quality is NOT a Spectator Sport.

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023